Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...
Crucially, Humira costs the NHS more than £500 million a year, a sum that NHS England wants to see fall through biosimilar use. Sandoz is one such company that hopes to offer the NHS savings ...
That's because IBD affects the immune system, and medications used to treat IBD—like Humira—weaken the immune system. For many people, the flu is a manageable illness, but for people who are ...